Q-omics provides the consensus-scored RNA5SP219 profile across patient tissues and cancer cell-line models. RNA5SP219 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RNA5SP219 is differentially expressed in 5, with the highest sampling consensus in STAD. Additionally, RNA5SP219 RNA expression shows 17,429 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight HNSC, STAD, and DLBC as cancer lineages where RNA5SP219 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNA5SP219 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNA5SP219 survival associations across molecular data types. RNA5SP219 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNA5SP219 RNA expression–survival associations across cancer types. High RNA5SP219 expression shows unfavorable associations in LUAD, ESCA and DLBC, but favorable associations in HNSC, SKCM and LUSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RNA5SP219 RNA expression.
This table summarizes RNA5SP219 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNA5SP219. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNA5SP219 shows lower tumor expression in BRCA and KIRC and higher tumor expression in STAD, HNSC and KICH. The STAD box plot shows higher RNA5SP219 RNA expression in tumor versus normal tissue (log2 FC = +0.957, t-test p < 0.001).
This table shows molecular features associated with RNA5SP219 in patient tissues and cancer cell lines. In patient samples, RNA5SP219 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
